3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
3
Colorectal Neoplasms, Hereditary Nonpolyposis
3
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Urogenital Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplastic Syndromes, Hereditary
1
Neoplasms, Unknown Primary
1
Melanoma
1
Kidney Neoplasms
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Head and Neck Neoplasms
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Intraductal, Noninfiltrating
1
Brain Neoplasms
1
Interventions
pembrolizumab
59
Nivolumab
34
Cyclophosphamide
21
fludarabine
15
Paclitaxel
12
Ipilimumab
12
atezolizumab
11
Specimen Handling
11
Magnetic Resonance Spectroscopy
10
Carboplatin
10
Docetaxel
9
Cisplatin
9
Gemcitabine
8
Biopsy
8
durvalumab
7
aldesleukin
7
Radiosurgery
7
Interleukin-2
7
Bevacizumab
7
cemiplimab
6
Pemetrexed
6
fludarabine phosphate
5
avelumab
5
Radiotherapy
5
Drug Therapy
5
spartalizumab
4
epacadostat
4
enzalutamide
4
Taxes
4
Sirolimus
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Genetic Counseling
×
Gastrointestinal
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled